Up 77% in a month! What's going on with the Mesoblast share price?

MotleyFool01-07

We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Garry Singh
01-07
Garry Singh
Bullish bullish bullish

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501217172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501217172","market":"us","top_or_hot":-1,"title":"Up 77% in a month! What's going on with the Mesoblast share price?","media":"MotleyFool","content":"<div>\n<p>We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and...</p>\n\n<a href=\"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Up 77% in a month! What's going on with the Mesoblast share price?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUp 77% in a month! What's going on with the Mesoblast share price?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 11:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and...</p>\n\n<a href=\"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/","article_id":"2501217172","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501217172","pubTimestamp":1736219078,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration  for its Ryoncil  product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease . It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards  ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's se","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","MESO":"Mesoblast Limited","MSB.AU":"MESOBLAST LTD","BK7501":"新冠治疗股","BK7508":"医药生物股"},"translate_title":"一个月涨77%！Mesoblast股价怎么了？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1,"MSB.AU":1,"XAO.AU":1,"XJO.AU":1},"content_text":"We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and rose by a healthy 7.5%. But that gain pales against what the Mesoblast Ltd (ASX: MSB) share price delivered. Mesoblast shares had a blowout year; no other way to put it. This pharmaceutical company began the year at just 31 cents a share. But by the time December wrapped up, those same shares were going for $3.10. That makes Mesoblast a certified ten-bagger, with investors enjoying a phenomenal return of 900% over the year.  This places the Mesoblast share price amongst the top five performers on the entire All Ordinaries (ASX: XAO) Index for 2024. A good chunk of those returns have come over just the past month alone. Back in early December, Mesoblast stock was going for $1.66. At today's pricing of $2.94 a share (at the time of writing), that means this company has vaulted 77% higher over the past month alone. The Mesoblast share price has also jumped 162.5% over the past six months. Check this all out for yourself below:  How has the Mesoblast share price rocketed by 73% in a month? The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration (FDA) for its Ryoncil (remestemcel-L) product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease (SR-aGvHD). It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards (barring some sporadic profit-taking) ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's see what the rest of this year brings to this company's jubilant investors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":389870868320600,"gmtCreate":1736227142342,"gmtModify":1736227146319,"author":{"id":"4110059374530302","authorId":"4110059374530302","name":"Garry Singh","avatar":"https://community-static.tradeup.com/news/99b22414e11c35bc798debe4746152b6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4110059374530302","authorIdStr":"4110059374530302"},"htmlText":"Bullish bullish bullish&nbsp;","listText":"Bullish bullish bullish&nbsp;","text":"Bullish bullish bullish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389870868320600","repostId":2501217172,"repostType":2,"repost":{"id":"2501217172","kind":"highlight","pubTimestamp":1736219078,"share":"https://ttm.financial/m/news/2501217172?lang=&edition=fundamental","pubTime":"2025-01-07 11:04","market":"us","language":"en","title":"Up 77% in a month! What's going on with the Mesoblast share price?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501217172","media":"MotleyFool","summary":"The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration  for its Ryoncil  product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease . It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards  ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's se","content":"<html><body><div> <p>We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the<strong> S&amp;P/ASX 200 Index</strong> (ASX: XJO) minted around two dozen new all-time record highs last year and rose by a healthy 7.5%. But that gain pales against what the <strong>Mesoblast Ltd</strong> (ASX: MSB) share price delivered.</p> <p>Mesoblast shares had a blowout year; no other way to put it. This pharmaceutical company began the year at just 31 cents a share. But by the time December wrapped up, those same shares were going for $3.10. That makes Mesoblast a certified ten-bagger, with investors enjoying a phenomenal return of 900% over the year. </p> <p>This places the Mesoblast share price amongst the top five performers on the entire <strong>All Ordinaries</strong> (ASX: XAO) Index for 2024.</p> <p>A good chunk of those returns have come over just the past month alone. Back in early December, Mesoblast stock was going for $1.66. At today's pricing of $2.94 a share (at the time of writing), that means this company has vaulted 77% higher over the past month alone. The Mesoblast share price has also jumped 162.5% over the past six months.</p> <p>Check this all out for yourself below:</p> <div></div> <h2>How has the Mesoblast share price rocketed by 73% in a month?</h2> <p>The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas.</p> <p>As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration (FDA) for its Ryoncil (remestemcel-L) product.</p> <p>Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease (SR-aGvHD). It is the only therapy that has gained approval for use in children two months and older in the United States.</p> <p>Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year.</p> <p>But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards (barring some sporadic profit-taking) ever since.</p> <p>So the Mesoblast share price is entering 2025 at a notable high. Let's see what the rest of this year brings to this company's jubilant investors.</p> </div></body></html>","source":"motleyfoolau_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Up 77% in a month! What's going on with the Mesoblast share price?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUp 77% in a month! What's going on with the Mesoblast share price?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 11:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and...</p>\n\n<a href=\"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","MESO":"Mesoblast Limited","MSB.AU":"MESOBLAST LTD","BK7501":"新冠治疗股","BK7508":"医药生物股"},"source_url":"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2501217172","content_text":"We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and rose by a healthy 7.5%. But that gain pales against what the Mesoblast Ltd (ASX: MSB) share price delivered. Mesoblast shares had a blowout year; no other way to put it. This pharmaceutical company began the year at just 31 cents a share. But by the time December wrapped up, those same shares were going for $3.10. That makes Mesoblast a certified ten-bagger, with investors enjoying a phenomenal return of 900% over the year.  This places the Mesoblast share price amongst the top five performers on the entire All Ordinaries (ASX: XAO) Index for 2024. A good chunk of those returns have come over just the past month alone. Back in early December, Mesoblast stock was going for $1.66. At today's pricing of $2.94 a share (at the time of writing), that means this company has vaulted 77% higher over the past month alone. The Mesoblast share price has also jumped 162.5% over the past six months. Check this all out for yourself below:  How has the Mesoblast share price rocketed by 73% in a month? The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration (FDA) for its Ryoncil (remestemcel-L) product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease (SR-aGvHD). It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards (barring some sporadic profit-taking) ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's see what the rest of this year brings to this company's jubilant investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501217172"}